The impact of pretransplant donor-specific antibodies on graft outcome in renal transplantation: A six-year follow-up study

Clinics

Volumn 67, Issue 4, 2012, Pages 355-361

  David Neto, Elias ^a   Souza, Patricia Soares ^a   Panajotopoulos, Nicolas ^a   Rodrigues, Helcio ^a   Ventura, Carlucci Gualberto ^a   David, Daisa Silva Ribeiro ^a   Lemos, Francine Brambate Carvalhinho ^a   Agena, Fabiana ^a   Nahas, William Carlos ^a   Kalil, Jorge Elias ^a   Castro, Maria Cristina Ribeiro ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Donor specific antibodies; DSA; Luminex; Renal transplantation; Solid phase assay

Indexed keywords

ANTIBODY; CYCLOSPORIN; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; BLOOD GROUP TYPING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DONOR; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTIBODIES; BLOOD GROUPING AND CROSSMATCHING; CROSS-SECTIONAL STUDIES; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TISSUE DONORS; YOUNG ADULT;

EID: 84860140162     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(04)09     Document Type: Article

References (17)

1. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation. 2009;87(11):1681-8. http:// dx.doi.org/10.1097/TP.0b013e3181a5e034.
2. Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation. 2008;85(8):1200-4. http://dx.doi.org/10.1097/TP.0b013e31816b1c37.
3. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010;21(8):1398-406.
4. Patel AM, Pancoska C, Mulgaonkar S, Weng FL. Renal transplantation in patients with pretransplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant. 2007;7(10):2371-7. http:// dx.doi.org/10.1111/j.1600-6143.2007.01944.x.
5. Vlad G, Ho EK, Vasilescu ER, Colovai AI, Stokes MB, Markowitz GS, et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol. 2009;70(8):589-94. http://dx.doi.org/10.1016/j.humimm.2009.04.018.
6. Pereira L, Castro M, Ventura C, Reis F, Sumita N, Sato MI, et al. The MODIFY Study in renal transplantation (Modification of doses to improve function through the years). Am J Transplant. 2005;11(Suppl 5):466.
7. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753-60. http://dx.doi.org/10.1111/j.1600-6143.2008.02159.x.
8. David-Neto E, Prado E, Beutel A, Ventura CG, Siqueira SA, Hung J, et al. C4d-positive chronic rejection: a frequent entity with a poor outcome. Transplantation. 2007;84(11):1391-8. http://dx.doi.org/10.1097/01.tp.0000288807.52520.5e.
9. Kedainis RL, Koch MJ, Brennan DC, Liapis H. Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival. Am J Transplant. 2009;9(4):812-9. http://dx.doi.org/10.1111/j.1600-6143.2009.02555.x.
10. Lefaucheur C, Suberbielle-Boissel C, Hill GS, Nochy D, Andrade J, Antoine C, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Contrib Nephrol. 2009;162:1-12. http://dx.doi.org/10.1159/000170788.
11. Rafiq MA, de Boccardo G, Schroppel B, Bromberg JS, Sehgal V, Dinavahi R, et al. Differential outcomes in 3 types of acute antibody-mediated rejection. Clin Transplant. 2009;23(6):951-7. http://dx.doi.org/10.1111/j.1399-0012.2009.01036.x.
12. Loupy A, Suberbielle-Boissel C, Hill GS, Lefaucheur C, Anglicheau D, Zuber J, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant. 2009;9(11):2561-70. http://dx.doi.org/10.1111/j.1600-6143.2009.02813.x.
13. Seemayer CA, Gaspert A, Nickeleit V, Mihatsch MJ. C4d staining of renal allograft biopsies: a comparative analysis of different staining techniques. Nephrol Dial Transplant. 2007;22(2):568-76.
14. Nadasdy GM, Bott C, Cowden D, Pelletier R, Ferguson R, Nadasdy T. Comparative study for the detection of peritubular capillary C4d deposition in human renal allografts using different methodologies. Hum Pathol. 2005;36(11):1178-95. http://dx.doi.org/10.1016/j.humpath.2005.08.002.
15. Ho EK, Vasilescu ER, Colovai AI, Stokes MB, Hallar M, Markowitz GS, et al. Sensitivity, specificity and clinical relevance of different crossmatching assays in deceased-donor renal transplantation. Transpl Immunol. 2008;20(1-2):61-7. http://dx.doi.org/10.1016/j.trim.2008.09.013.
16. Lachmann N, Terasaki PI, Budde K, Liefeldt L, Kahl A, Reinke P, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation. 2009;87(10):1505-13 http://dx.doi.org/10.1097/TP.0b013e3181a44206.
17. Aubert V, Venetz JP, Pantaleo G, Pascual M. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol. 2009;70(8):580-3. http://dx.doi.org/10.1016/j.humimm.2009.04.011.